Humoral immune response to functional regions of human cytomegalovirus glycoprotein B
Sera from patients with primary human cytomegalovirus (HCMV) infections, both acute and convalescent phase, and from HCMV‐seropositive healthy subjects were analyzed to determine whether the sera would recognize antigenic domains on HCMV glycoprotein B (gB) that function in virion infectivity and sp...
Saved in:
Published in | Journal of medical virology Vol. 52; no. 4; pp. 451 - 459 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
New York
Wiley Subscription Services, Inc., A Wiley Company
01.08.1997
Wiley-Liss |
Subjects | |
Online Access | Get full text |
ISSN | 0146-6615 1096-9071 |
DOI | 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J |
Cover
Abstract | Sera from patients with primary human cytomegalovirus (HCMV) infections, both acute and convalescent phase, and from HCMV‐seropositive healthy subjects were analyzed to determine whether the sera would recognize antigenic domains on HCMV glycoprotein B (gB) that function in virion infectivity and spread of virus from cell to cell. The intact gB molecule, amino‐terminal derivatives of different lengths, and internal deletion derivatives were expressed in eukaryotic cells and reacted by immunofluorescence with the sera. All convalescent‐phase sera and most sera from healthy seropositive individuals reacted with full‐length gB and with an amino‐terminal derivative containing 687 amino acids (aa), gB‐(1–687); approximately half of the sera recognized an amino‐terminal derivative of 447 aa, gB‐(1–447), and one‐third reacted with the shortest deletion derivative of 258 aa, gB‐(1–258). Of the acute‐phase sera, 77% recognized intact gB and gB‐(1–687), 32% recognized gB‐(1–447), and 14% recognized gB‐(1–258). Deletion of aa 548 to 618 dramatically reduced the percentage of reactive sera, whereas deletion of aa 411 to 447 had a minor impact on reactivity of sera. To investigate the epitope specificity of human antibodies to gB, we carried out competition experiments between human sera with neutralizing activity and selected monoclonal antibodies (mAbs) to conformational epitopes on gB. We found that antibodies in human sera preclude syncytium formation in UB15‐11 glioblastoma cells constitutively expressing gB and compete with certain murine mAbs that block virus entry into cells and transmission of infection from cell to cell. Our results show that HCMV‐immune human sera contain antibodies to functional regions on gB, and the abundance of these antibodies in convalescent‐phase sera suggests that they may play a central role in limiting dissemination of virus in the host. J. Med. Virol. 52:451–459, 1997. © 1997 Wiley‐Liss, Inc. |
---|---|
AbstractList | Sera from patients with primary human cytomegalovirus (HCMV) infections, both acute and convalescent phase, and from HCMV-seropositive healthy subjects were analyzed to determine whether the sera would recognize antigenic domains on HCMV glycoprotein B (gB) that function in virion infectivity and spread of virus from cell to cell. The intact gB molecule, amino-terminal derivatives of different lengths, and internal deletion derivatives were expressed in eukaryotic cells and reacted by immunofluorescence with the sera. All convalescent-phase sera and most sera from healthy seropositive individuals reacted with full-length gB and with an amino-terminal derivative containing 687 amino acids (aa), gB-(1-687); approximately half of the sera recognized an amino-terminal derivative of 447 aa, gB-(1-447), and one-third reacted with the shortest deletion derivative of 258 aa, gB-(1-258). Of the acute-phase sera, 77% recognized intact gB and gB-(1-687), 32% recognized gB-(1-447), and 14% recognized gB-(1-258). Deletion of aa 548 to 618 dramatically reduced the percentage of reactive sera, whereas deletion of aa 411 to 447 had a minor impact on reactivity of sera. To investigate the epitope specificity of human antibodies to gB, we carried out competition experiments between human sera with neutralizing activity and selected monoclonal antibodies (mAbs) to conformational epitopes on gB. We found that antibodies in human sera preclude syncytium formation in UB15-11 glioblastoma cells constitutively expressing gB and compete with certain murine mAbs that block virus entry into cells and transmission of infection from cell to cell. Our results show that HCMV-immune human sera contain antibodies to functional regions on gB, and the abundance of these antibodies in convalescent-phase sera suggests that they may play a central role in limiting dissemination of virus in the host. Sera from patients with primary human cytomegalovirus (HCMV) infections, both acute and convalescent phase, and from HCMV-seropositive healthy subjects were analyzed to determine whether the sera would recognize antigenic domains on HCMV glycoprotein B (gB) that function in virion infectivity and spread of virus from cell to cell. The intact gB molecule, amino-terminal derivatives of different lengths, and internal deletion derivatives were expressed in eukaryotic cells and reacted by immunofluorescence with the sera. All convalescent-phase sera and most sera from healthy seropositive individuals reacted with full-length gB and with an amino-terminal derivative containing 687 amino acids (aa), gB-(1-687); approximately half of the sera recognized an amino-terminal derivative of 447 aa, gB-(1-447), and one-third reacted with the shortest deletion derivative of 258 aa, gB-(1-258). Of the acute-phase sera, 77% recognized intact gB and gB-(1-687), 32% recognized gB-(1-447), and 14% recognized gB-(1-258). Deletion of aa 548 to 618 dramatically reduced the percentage of reactive sera, whereas deletion of aa 411 to 447 had a minor impact on reactivity of sera. To investigate the epitope specificity of human antibodies to gB, we carried out competition experiments between human sera with neutralizing activity and selected monoclonal antibodies (mAbs) to conformational epitopes on gB. We found that antibodies in human sera preclude syncytium formation in UB15-11 glioblastoma cells constitutively expressing gB and compete with certain murine mAbs that block virus entry into cells and transmission of infection from cell to cell. Our results show that HCMV-immune human sera contain antibodies to functional regions on gB, and the abundance of these antibodies in convalescent-phase sera suggests that they may play a central role in limiting dissemination of virus in the host.Sera from patients with primary human cytomegalovirus (HCMV) infections, both acute and convalescent phase, and from HCMV-seropositive healthy subjects were analyzed to determine whether the sera would recognize antigenic domains on HCMV glycoprotein B (gB) that function in virion infectivity and spread of virus from cell to cell. The intact gB molecule, amino-terminal derivatives of different lengths, and internal deletion derivatives were expressed in eukaryotic cells and reacted by immunofluorescence with the sera. All convalescent-phase sera and most sera from healthy seropositive individuals reacted with full-length gB and with an amino-terminal derivative containing 687 amino acids (aa), gB-(1-687); approximately half of the sera recognized an amino-terminal derivative of 447 aa, gB-(1-447), and one-third reacted with the shortest deletion derivative of 258 aa, gB-(1-258). Of the acute-phase sera, 77% recognized intact gB and gB-(1-687), 32% recognized gB-(1-447), and 14% recognized gB-(1-258). Deletion of aa 548 to 618 dramatically reduced the percentage of reactive sera, whereas deletion of aa 411 to 447 had a minor impact on reactivity of sera. To investigate the epitope specificity of human antibodies to gB, we carried out competition experiments between human sera with neutralizing activity and selected monoclonal antibodies (mAbs) to conformational epitopes on gB. We found that antibodies in human sera preclude syncytium formation in UB15-11 glioblastoma cells constitutively expressing gB and compete with certain murine mAbs that block virus entry into cells and transmission of infection from cell to cell. Our results show that HCMV-immune human sera contain antibodies to functional regions on gB, and the abundance of these antibodies in convalescent-phase sera suggests that they may play a central role in limiting dissemination of virus in the host. Sera from patients with primary human cytomegalovirus (HCMV) infections, both acute and convalescent phase, and from HCMV‐seropositive healthy subjects were analyzed to determine whether the sera would recognize antigenic domains on HCMV glycoprotein B (gB) that function in virion infectivity and spread of virus from cell to cell. The intact gB molecule, amino‐terminal derivatives of different lengths, and internal deletion derivatives were expressed in eukaryotic cells and reacted by immunofluorescence with the sera. All convalescent‐phase sera and most sera from healthy seropositive individuals reacted with full‐length gB and with an amino‐terminal derivative containing 687 amino acids (aa), gB‐(1–687); approximately half of the sera recognized an amino‐terminal derivative of 447 aa, gB‐(1–447), and one‐third reacted with the shortest deletion derivative of 258 aa, gB‐(1–258). Of the acute‐phase sera, 77% recognized intact gB and gB‐(1–687), 32% recognized gB‐(1–447), and 14% recognized gB‐(1–258). Deletion of aa 548 to 618 dramatically reduced the percentage of reactive sera, whereas deletion of aa 411 to 447 had a minor impact on reactivity of sera. To investigate the epitope specificity of human antibodies to gB, we carried out competition experiments between human sera with neutralizing activity and selected monoclonal antibodies (mAbs) to conformational epitopes on gB. We found that antibodies in human sera preclude syncytium formation in UB15‐11 glioblastoma cells constitutively expressing gB and compete with certain murine mAbs that block virus entry into cells and transmission of infection from cell to cell. Our results show that HCMV‐immune human sera contain antibodies to functional regions on gB, and the abundance of these antibodies in convalescent‐phase sera suggests that they may play a central role in limiting dissemination of virus in the host. J. Med. Virol. 52:451–459, 1997. © 1997 Wiley‐Liss, Inc. |
Author | Tugizov, Sharof Navarro, David Lennette, Evelyne Pereira, Lenore |
Author_xml | – sequence: 1 givenname: David surname: Navarro fullname: Navarro, David organization: Division of Oral Biology, School of Dentistry, University of California San Francisco, San Francisco, California – sequence: 2 givenname: Evelyne surname: Lennette fullname: Lennette, Evelyne organization: Virolab, Berkeley, California – sequence: 3 givenname: Sharof surname: Tugizov fullname: Tugizov, Sharof organization: Division of Oral Biology, School of Dentistry, University of California San Francisco, San Francisco, California – sequence: 4 givenname: Lenore surname: Pereira fullname: Pereira, Lenore email: pereira@itsa.ucsf.edu organization: Division of Oral Biology, School of Dentistry, University of California San Francisco, San Francisco, California |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2788343$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9260696$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkUlv1DAYhiNUVKaFn4CUA0LtIYO3xPawSCXALCrMAVqOnxyPM6Qk8WAnwPx7HDKaC0iVD16-14-X5yw6aW1roug1RlOMEHlx8XmZLy8xklkiEccXWEqOxGVKZuwVS_FsdrV8l6w-3mLxhk7RNF-_JMnqQTQ57jiJJgizLMkynD6Kzry_QwgJSchpdCpJhjKZTaKbRd9Yp-q4apq-NbEzfmdbb-LOxmXf6q6ybag6sw0DH9sy_tY3qo31vrON2ara_qxc7-Ntvdd252xnqjZ--zh6WKramyeH_jy6-fD-S75IrtfzZX51nWiWYZEQXghebopCSVGWaGNIRniahrsJRnBa6DBnHGOG09Ao16wUpjB0sykFNtrQ8-j5yA0n_-iN76CpvDZ1rVpjew9cEiwQT-8N4owiSdAQfHoI9kVjNrBzVaPcHg4fFurPDnXltapLp1pd-WOMcCEoo_T4YO2s986UxwRGMOgFGPTCIAsGWTDqhZQAg6AXIOiFv3qBAoJ8DQRWgXs7cn9Vtdn_A72H-T_kuBDAyQiufGd-H8HKfYeMU57C10_zgTfPc7kARv8A2qjGOg |
CODEN | JMVIDB |
Cites_doi | 10.1099/0022-1317-70-4-979 10.1002/jmv.1890430115 10.1093/infdis/174.2.387 10.1093/infdis/164.5.835 10.1099/0022-1317-68-5-1457 10.1093/infdis/161.2.214 10.1099/0022-1317-72-12-3017 10.1128/JCM.21.4.517-521.1985 10.1128/JVI.66.9.5290-5297.1992 10.1016/S0092-8674(00)81054-5 10.1099/0022-1317-73-9-2375 10.1128/JVI.65.3.1644-1648.1991 10.1128/IAI.39.1.100-108.1983 10.1093/infdis/158.2.449 10.1099/0022-1317-71-10-2443 10.1128/JVI.64.3.1079-1085.1990 10.1016/0042-6822(88)90549-1 10.1056/NEJM198208193070804 10.1099/0022-1317-77-1-61 10.1073/pnas.90.1.104 10.1128/IAI.36.3.933-942.1982 10.1099/0022-1317-73-4-983 10.1099/0022-1317-73-11-2913 10.1128/JVI.70.1.78-83.1996 10.1128/JVI.65.1.138-146.1991 10.1002/jmv.1890430412 10.1002/(SICI)1096-9071(199606)49:2<124::AID-JMV9>3.0.CO;2-7 10.1093/clinids/12.Supplement_7.S827 10.1006/viro.1994.1291 10.1006/viro.1995.1290 10.1128/JVI.58.2.661-664.1986 10.1007/978-1-4757-9942-2 10.1006/viro.1996.0040 10.1128/JVI.62.9.3309-3318.1988 10.1093/infdis/174.3.606 10.1016/0264-410X(90)90135-9 10.1006/viro.1993.1575 10.1128/JVI.67.2.703-710.1993 10.1093/infdis/171.6.1599 10.1093/infdis/165.2.381 10.1016/0042-6822(84)90331-3 10.1128/JVI.62.3.1066-1070.1988 10.1128/JVI.63.5.1995-2001.1989 10.1016/0166-0934(89)90129-8 |
ContentType | Journal Article |
Copyright | Copyright © 1997 Wiley‐Liss, Inc. 1997 INIST-CNRS |
Copyright_xml | – notice: Copyright © 1997 Wiley‐Liss, Inc. – notice: 1997 INIST-CNRS |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7U9 H94 7X8 |
DOI | 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1096-9071 |
EndPage | 459 |
ExternalDocumentID | 9260696 2788343 10_1002__SICI_1096_9071_199708_52_4_451__AID_JMV18_3_0_CO_2_J JMV18 ark_67375_WNG_199GCC9H_4 |
Genre | article Research Support, U.S. Gov't, P.H.S Journal Article |
GrantInformation_xml | – fundername: National Institutes of Health, Public Health Service funderid: EY10138; EY11223 – fundername: NEI NIH HHS grantid: EY10138 – fundername: NEI NIH HHS grantid: EY11223 |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3O- 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFNX AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AI. AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS ECGQY EJD ELTNK EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E VH1 W8V W99 WBKPD WHG WIB WIH WIJ WIK WJL WNSPC WOHZO WQJ WXI WXSBR WYISQ X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~KM ~WT AAHHS ACCFJ AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE RGB RWI WRC WUP AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7U9 H94 7X8 |
ID | FETCH-LOGICAL-c4618-27b87fdbba98ff0de26275526084215bc262471141515137c4f8ebe3ddf81ece3 |
IEDL.DBID | DR2 |
ISSN | 0146-6615 |
IngestDate | Fri Jul 11 08:06:53 EDT 2025 Fri Jul 11 15:05:35 EDT 2025 Wed Feb 19 01:12:40 EST 2025 Mon Jul 21 09:15:44 EDT 2025 Tue Jul 01 01:33:10 EDT 2025 Wed Jan 22 16:25:09 EST 2025 Tue Sep 09 05:32:52 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Infection Virus Human Antibody Herpesviridae Dissemination Infectivity Viral disease Betaherpesvirinae Humoral immunity Human cytomegalovirus Neutralization |
Language | English |
License | http://doi.wiley.com/10.1002/tdm_license_1.1 CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4618-27b87fdbba98ff0de26275526084215bc262471141515137c4f8ebe3ddf81ece3 |
Notes | National Institutes of Health, Public Health Service - No. EY10138; No. EY11223 ArticleID:JMV18 ark:/67375/WNG-199GCC9H-4 istex:7E4BFAB75F6EE35DA098462053495D9E39B39C82 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 9260696 |
PQID | 16309205 |
PQPubID | 23462 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_79218075 proquest_miscellaneous_16309205 pubmed_primary_9260696 pascalfrancis_primary_2788343 crossref_primary_10_1002__SICI_1096_9071_199708_52_4_451__AID_JMV18_3_0_CO_2_J wiley_primary_10_1002_SICI_1096_9071_199708_52_4_451_AID_JMV18_3_0_CO_2_J_JMV18 istex_primary_ark_67375_WNG_199GCC9H_4 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | August 1997 |
PublicationDateYYYYMMDD | 1997-08-01 |
PublicationDate_xml | – month: 08 year: 1997 text: August 1997 |
PublicationDecade | 1990 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: New York, NY – name: United States |
PublicationTitle | Journal of medical virology |
PublicationTitleAlternate | J. Med. Virol |
PublicationYear | 1997 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss |
References | Ho M (1991): "Cytomegalovirus: Biology and Infection." New York: Plenum. Lasry S, Deny P, Asselot C, Rauzy M, Boucher J, Guyot C, Leroux MC, Livartowski A, Reinert P, Nicolas JC (1996): Interstrain variations in the cytomegalovirus (CMV) glycoprotein B gene sequence among CMV-infected children attending six day care centers. Journal of Infectious Diseases 174: 606-609. Banks T, Huo B, Kousoulas K, Spaete R, Pachl C, Pereira L (1989): A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein. Journal of General Virology 70: 979-985. Cremer N, Cossen CK, Shell GR, Pereira L (1985): Antibody response to cytomegalovirus polypeptides captured by monoclonal antibodies on the solid phase in enzyme immunoassays. Journal of Clinical Microbiology 21: 517-521. Marshall GS, Stout GG, Knights ME, Rabalais GP, Ashley R, Miller H, Rossier E (1994): Ontogeny of glycoprotein gB-specific antibody and neutralizing activity during natural cytomegalovirus infection. Journal of Medical Virology 43: 77-83. Pereira L, Stagno S, Hoffman M, Volanakis J (1983): Cytomegalovirus infected cell polypeptides immune precipitated by children with congenital and perinatal cytomegalovirus infections. Infection and Immunity 39: 100-108. Detrick B, Rhame J, Wang Y, Nagineni CN, Hooks JJ (1996): Cytomegalovirus replication in human retinal pigment epithelial cells. Altered expression of viral early proteins. Investigative Ophthalmology and Visual Science 37: 814-825. Wagner B, Kropff B, Kalbacher H, Britt W, Sundqvist VA, Ostberg L, Mach M (1992): A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. Journal of Virology 66: 5290-5297. Liu YC, Kari B, Gehrz RC (1988): Human immune responses to major human cytomegalovirus glycoprotein. Journal of Virology 62: 1066-1070. Pereira L, Hoffman M, Cremer N (1982): Electrophoretic analysis of polypeptides immune precipitated from extracts of cytomegalovirus infected cells by human sera. Infection and Immunity 36: 933-942. Navarro D, Paz P, Tugizov S, Topp K, LaVail J, Pereira L (1993): Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, the transmission of infection from cell to cell, and fusion of infected cells. Virology 197: 143-158. Masuho Y, Matsumoto Y, Sugano T, Fujinaga S, Minamishima Y (1987): Human monoclonal antibodies neutralizing human cytomegalovirus. Journal of General Virology 68: 1457-1461. Lussenhop NO, Goertz R, Wabuke-Bunoti M, Gehrz R, Kari B (1988): Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies. Virology 164: 362-372. Schoppel K, Hassfurther E, Britt W, Ohlin M, Borrebaeck CA, Mach M (1996): Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216: 133-145. Liu Y-NC, Klaus A, Kari B, Stinski MF, Eckhardt K, Gehrz RC (1991): The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B- and T-cell immune responses in ns. Journal of Virology 65: 1644-48. Pass RF, August AM, Dworsky M, Reynolds DW (1982): Cytomegalovirus infection in a day-care center. New England Journal of Medicine 307: 477-479. Ayata M, Sugano T, Murayama T, Sakamuro D, Takegami T, Matsumoto Y, Furukawa T (1994): Different antibody response to a neutralizing epitope of human cytomegalovirus glycoprotein B among seropositive individuals. Journal of Medical Virology 43: 386-392. Andreoni M, Faircloth M, Vulgar L, Britt W (1989): A rapid micro-neutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. Journal of Virological Methods 23: 157-168. Brown JM, Kaneshima H, Mocarski ES (1995): Dramatic interstrain differences in the replication of human cytomegalovirus in SCID-hu mice. Journal of Infectious Diseases 171: 1599-1603. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL (1996): The human cytomegalovirus US 11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84: 769-799. Meyer H, Masuho Y, Mach M (1990): The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. Journal of General Virology 71: 2443-2450. Adler SP (1996): Current prospects for immunization against cytomegaloviral disease. Infectious Agents and Disease 5: 29-35. Mocarski ES, Bonyhadi M, Salimi S, McCune JM, Kaneshima H (1993): Human cytomegalovirus in a SCID-hu mouse: Thymic epithelial cells are prominent targets of viral replications. Proceedings of the National Academy of Sciences of the United States of America 90: 104-108. Ohlin M, Sundqvist VA, Mach M, Wahren B, Borrebaeck CA (1993): Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. Journal of Virology 67: 703-710. Qadri I, Navarro D, Paz P, Pereira L (1992): Assembly of conformation-dependent neutralizing domains on human cytomegalovirus glycoprotein B. Journal of General Virology 73: 2913-2921. Rasmussen L, Matkin C, Spaete R, Pachl C, Merigan TC (1991): Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. Journal of Infectious Diseases 164: 835-842. Britt WJ, Vugler L, Stephens EB (1988): Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). Journal of Virology 62: 3309-3318. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR (1996): Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. Journal of Virology 70: 78-83. Drew L (1988): Cytomegalovirus infection in patients with AIDS. Journal of Infectious Diseases 158: 449-456. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990): Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. Journal of Virology 64: 1079-1085. Pereira L (1994): Function of glycoprotein B homologues of the family herpesviridae. Infectious Agents and Disease 3: 9-28. Hopkins JI, Fiander AN, Evands AS, Delchambre M, Gheysen D, Borysiewicz LK (1996): Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B. Journal of Medical Virology 49: 124-131. Utz U, Britt W, Vugler L, Mach M (1989): Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. Journal of Virology 5: 1995-2001. Tugizov S, Maidji E, Pereira L (1996): Role of apical and basolateral membranes in replication of human cytomegalovirus in polarized retinal pigment epithelial cells. Journal of General Virology 77: 61-74. Marshall GS, Rabalais GP, Stout GG, Waldeyer SL (1992): Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. Journal of Infectious Diseases 165: 381-384. Britt WJ, Vugler LG (1990): Antiviral antibody responses in mothers and their newborn infants with clinical and subclinical congenital cytomegalovirus infections. Journal of Infectious Diseases 161: 214-219. Meyer H, Sundquist V-A, Pereira L, Mach M (1992): Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. Journal of General Virology 73: 2375-2383. Tugizov S, Wang Y, Qadri I, Navarro D, Maidji E, Pereira L (1995): Mutated forms of human cytomegalovirus glycoprotein B are impaired in inducing syncytium formation. Virology 209: 580-591. Tugizov S, Navarro D, Paz P, Wang Y, Qadri I, Pereira L (1994): Function of human cytomegalovirus glycoprotein B: Syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies. Virology 201: 263-276. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K (1990): Vaccines for the prevention of human cytomegalovirus infection. Review of Infectious Diseases 12: 827-838. Kniess N, Mach M, Fay J, Britt WJ (1991): Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. Journal of Virology 65: 138-146. Wang JB, Adler SP, Hempfling S, Burke RL, Duliege AM, Starr SE, Plotkin SA (1996): Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. Journal of Infectious Diseases 174: 387-392. Silvestri M, Sundqvist VA, Ruden U, Wahren B (1991): Characterization of a major antigenic region on gp55 of human cytomegalovirus. Journal of General Virology 72: 3017-3023. Basgoz N, Qadri I, Navarro D, Sears A, Lennette E, Youngblom J, Pereira L (1992): The amino terminus of human cytomegalovirus glycoprotein B contains epitopes that vary among strains. Journal of General Virology 73: 983-988. Gonczol E, Hudecz F, Ianacone J, Dietzschold B, Starr S, Plotkin SA (1986): Immune responses to isolated human cytomegalovirus envelope proteins. Journal of Virology 58: 661-664. Gonczol E, Ianacone J, Ho WZ, Starr S, Meigneir B, Plotkin S (1990): Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8: 130-136. Pereira L, Hoffman M, Tatsuno M, Dondero D (1984): Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies. Virology 139: 73-86. 1982; 36 1989; 5 1993; 67 1989; 23 1990; 12 1982; 307 1992; 165 1986; 58 1991; 72 1994 1993 1988; 164 1993; 90 1996; 70 1991 1983; 39 1985; 21 1996; 37 1995; 171 1994; 43 1992; 73 1990; 161 1996; 77 1987; 68 1991; 164 1994; 201 1990; 64 1991; 65 1995; 209 1989; 70 1984; 139 1988; 158 1996; 84 1988; 62 1996; 174 1996; 5 1996; 49 1994; 3 1992; 66 1990; 8 1993; 197 1990; 71 1996; 216 Pereira (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB35) 1983; 39 Britt (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB7) 1990; 161 Pereira (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB36) 1984; 139 Britt (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB8) 1988; 62 Qadri (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB41) 1992; 73 Silvestri (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB44) 1991; 72 Mocarski (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB29) 1993; 90 Liu (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB22) 1991; 65 Wiertz (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB51) 1996; 84 Pereira (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB37) 1991 Kniess (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB19) 1991; 65 Tugizov (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB46) 1995; 209 Ohlin (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB31) 1993; 67 Rasmussen (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB42) 1991; 164 Pass (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB32) 1982; 307 Adler (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB1) 1996; 5 Alford (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB2) 1993 Utz (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB48) 1989; 5 Basgoz (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB6) 1992; 73 Pereira (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB38) 1993 Detrick (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB13) 1996; 37 Cremer (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB12) 1985; 21 Wang (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB50) 1996; 174 Lussenhop (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB23) 1988; 164 Masuho (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB26) 1987; 68 Meyer (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB28) 1992; 73 Andreoni (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB3) 1989; 23 Lasry (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB20) 1996; 174 Marshall (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB24) 1992; 165 Hopkins (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB18) 1996; 49 Navarro (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB30) 1993; 197 Pereira (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB34) 1982; 36 Schoppel (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB43) 1996; 216 Drew (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB14) 1988; 158 Tugizov (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB47) 1996; 77 Gonczol (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB15) 1986; 58 Ho (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB17) 1991 Ayata (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB4) 1994; 43 Pereira (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB33) 1994; 3 Wagner (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB49) 1992; 66 Britt (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB9) 1990; 64 Brown (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB10) 1995; 171 Banks (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB5) 1989; 70 Meyer (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB27) 1990; 71 Cha (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB11) 1996; 70 Tugizov (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB45) 1994; 201 Marshall (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB25) 1994; 43 Plotkin (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB39) 1994 Liu (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB21) 1988; 62 Plotkin (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB40) 1990; 12 Gonczol (10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB16) 1990; 8 |
References_xml | – reference: Pereira L, Hoffman M, Tatsuno M, Dondero D (1984): Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies. Virology 139: 73-86. – reference: Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR (1996): Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. Journal of Virology 70: 78-83. – reference: Tugizov S, Wang Y, Qadri I, Navarro D, Maidji E, Pereira L (1995): Mutated forms of human cytomegalovirus glycoprotein B are impaired in inducing syncytium formation. Virology 209: 580-591. – reference: Pereira L (1994): Function of glycoprotein B homologues of the family herpesviridae. Infectious Agents and Disease 3: 9-28. – reference: Adler SP (1996): Current prospects for immunization against cytomegaloviral disease. Infectious Agents and Disease 5: 29-35. – reference: Navarro D, Paz P, Tugizov S, Topp K, LaVail J, Pereira L (1993): Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, the transmission of infection from cell to cell, and fusion of infected cells. Virology 197: 143-158. – reference: Kniess N, Mach M, Fay J, Britt WJ (1991): Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. Journal of Virology 65: 138-146. – reference: Detrick B, Rhame J, Wang Y, Nagineni CN, Hooks JJ (1996): Cytomegalovirus replication in human retinal pigment epithelial cells. Altered expression of viral early proteins. Investigative Ophthalmology and Visual Science 37: 814-825. – reference: Brown JM, Kaneshima H, Mocarski ES (1995): Dramatic interstrain differences in the replication of human cytomegalovirus in SCID-hu mice. Journal of Infectious Diseases 171: 1599-1603. – reference: Tugizov S, Maidji E, Pereira L (1996): Role of apical and basolateral membranes in replication of human cytomegalovirus in polarized retinal pigment epithelial cells. Journal of General Virology 77: 61-74. – reference: Andreoni M, Faircloth M, Vulgar L, Britt W (1989): A rapid micro-neutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. Journal of Virological Methods 23: 157-168. – reference: Wagner B, Kropff B, Kalbacher H, Britt W, Sundqvist VA, Ostberg L, Mach M (1992): A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. Journal of Virology 66: 5290-5297. – reference: Lasry S, Deny P, Asselot C, Rauzy M, Boucher J, Guyot C, Leroux MC, Livartowski A, Reinert P, Nicolas JC (1996): Interstrain variations in the cytomegalovirus (CMV) glycoprotein B gene sequence among CMV-infected children attending six day care centers. Journal of Infectious Diseases 174: 606-609. – reference: Utz U, Britt W, Vugler L, Mach M (1989): Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. Journal of Virology 5: 1995-2001. – reference: Wang JB, Adler SP, Hempfling S, Burke RL, Duliege AM, Starr SE, Plotkin SA (1996): Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. Journal of Infectious Diseases 174: 387-392. – reference: Pereira L, Hoffman M, Cremer N (1982): Electrophoretic analysis of polypeptides immune precipitated from extracts of cytomegalovirus infected cells by human sera. Infection and Immunity 36: 933-942. – reference: Pereira L, Stagno S, Hoffman M, Volanakis J (1983): Cytomegalovirus infected cell polypeptides immune precipitated by children with congenital and perinatal cytomegalovirus infections. Infection and Immunity 39: 100-108. – reference: Schoppel K, Hassfurther E, Britt W, Ohlin M, Borrebaeck CA, Mach M (1996): Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216: 133-145. – reference: Britt WJ, Vugler L, Stephens EB (1988): Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). Journal of Virology 62: 3309-3318. – reference: Ho M (1991): "Cytomegalovirus: Biology and Infection." New York: Plenum. – reference: Basgoz N, Qadri I, Navarro D, Sears A, Lennette E, Youngblom J, Pereira L (1992): The amino terminus of human cytomegalovirus glycoprotein B contains epitopes that vary among strains. Journal of General Virology 73: 983-988. – reference: Marshall GS, Stout GG, Knights ME, Rabalais GP, Ashley R, Miller H, Rossier E (1994): Ontogeny of glycoprotein gB-specific antibody and neutralizing activity during natural cytomegalovirus infection. Journal of Medical Virology 43: 77-83. – reference: Mocarski ES, Bonyhadi M, Salimi S, McCune JM, Kaneshima H (1993): Human cytomegalovirus in a SCID-hu mouse: Thymic epithelial cells are prominent targets of viral replications. Proceedings of the National Academy of Sciences of the United States of America 90: 104-108. – reference: Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990): Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. Journal of Virology 64: 1079-1085. – reference: Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K (1990): Vaccines for the prevention of human cytomegalovirus infection. Review of Infectious Diseases 12: 827-838. – reference: Meyer H, Sundquist V-A, Pereira L, Mach M (1992): Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. Journal of General Virology 73: 2375-2383. – reference: Masuho Y, Matsumoto Y, Sugano T, Fujinaga S, Minamishima Y (1987): Human monoclonal antibodies neutralizing human cytomegalovirus. Journal of General Virology 68: 1457-1461. – reference: Pass RF, August AM, Dworsky M, Reynolds DW (1982): Cytomegalovirus infection in a day-care center. New England Journal of Medicine 307: 477-479. – reference: Gonczol E, Ianacone J, Ho WZ, Starr S, Meigneir B, Plotkin S (1990): Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8: 130-136. – reference: Liu Y-NC, Klaus A, Kari B, Stinski MF, Eckhardt K, Gehrz RC (1991): The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B- and T-cell immune responses in ns. Journal of Virology 65: 1644-48. – reference: Britt WJ, Vugler LG (1990): Antiviral antibody responses in mothers and their newborn infants with clinical and subclinical congenital cytomegalovirus infections. Journal of Infectious Diseases 161: 214-219. – reference: Ohlin M, Sundqvist VA, Mach M, Wahren B, Borrebaeck CA (1993): Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. Journal of Virology 67: 703-710. – reference: Ayata M, Sugano T, Murayama T, Sakamuro D, Takegami T, Matsumoto Y, Furukawa T (1994): Different antibody response to a neutralizing epitope of human cytomegalovirus glycoprotein B among seropositive individuals. Journal of Medical Virology 43: 386-392. – reference: Hopkins JI, Fiander AN, Evands AS, Delchambre M, Gheysen D, Borysiewicz LK (1996): Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B. Journal of Medical Virology 49: 124-131. – reference: Rasmussen L, Matkin C, Spaete R, Pachl C, Merigan TC (1991): Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. Journal of Infectious Diseases 164: 835-842. – reference: Silvestri M, Sundqvist VA, Ruden U, Wahren B (1991): Characterization of a major antigenic region on gp55 of human cytomegalovirus. Journal of General Virology 72: 3017-3023. – reference: Cremer N, Cossen CK, Shell GR, Pereira L (1985): Antibody response to cytomegalovirus polypeptides captured by monoclonal antibodies on the solid phase in enzyme immunoassays. Journal of Clinical Microbiology 21: 517-521. – reference: Meyer H, Masuho Y, Mach M (1990): The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. Journal of General Virology 71: 2443-2450. – reference: Qadri I, Navarro D, Paz P, Pereira L (1992): Assembly of conformation-dependent neutralizing domains on human cytomegalovirus glycoprotein B. Journal of General Virology 73: 2913-2921. – reference: Tugizov S, Navarro D, Paz P, Wang Y, Qadri I, Pereira L (1994): Function of human cytomegalovirus glycoprotein B: Syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies. Virology 201: 263-276. – reference: Gonczol E, Hudecz F, Ianacone J, Dietzschold B, Starr S, Plotkin SA (1986): Immune responses to isolated human cytomegalovirus envelope proteins. Journal of Virology 58: 661-664. – reference: Marshall GS, Rabalais GP, Stout GG, Waldeyer SL (1992): Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. Journal of Infectious Diseases 165: 381-384. – reference: Banks T, Huo B, Kousoulas K, Spaete R, Pachl C, Pereira L (1989): A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein. Journal of General Virology 70: 979-985. – reference: Lussenhop NO, Goertz R, Wabuke-Bunoti M, Gehrz R, Kari B (1988): Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies. Virology 164: 362-372. – reference: Drew L (1988): Cytomegalovirus infection in patients with AIDS. Journal of Infectious Diseases 158: 449-456. – reference: Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL (1996): The human cytomegalovirus US 11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84: 769-799. – reference: Liu YC, Kari B, Gehrz RC (1988): Human immune responses to major human cytomegalovirus glycoprotein. Journal of Virology 62: 1066-1070. – volume: 37 start-page: 814 year: 1996 end-page: 825 article-title: Cytomegalovirus replication in human retinal pigment epithelial cells. Altered expression of viral early proteins publication-title: Investigative Ophthalmology and Visual Science – start-page: 195 year: 1991 end-page: 198 – volume: 197 start-page: 143 year: 1993 end-page: 158 article-title: Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, the transmission of infection from cell to cell, and fusion of infected cells publication-title: Virology – volume: 164 start-page: 835 year: 1991 end-page: 842 article-title: Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans publication-title: Journal of Infectious Diseases – volume: 43 start-page: 386 year: 1994 end-page: 392 article-title: Different antibody response to a neutralizing epitope of human cytomegalovirus glycoprotein B among seropositive individuals publication-title: Journal of Medical Virology – volume: 62 start-page: 3309 year: 1988 end-page: 3318 article-title: Induction of complement‐dependent and ‐independent neutralizing antibodies by recombinant‐derived human cytomegalovirus gp55–116 (gB) publication-title: Journal of Virology – volume: 43 start-page: 77 year: 1994 end-page: 83 article-title: Ontogeny of glycoprotein gB‐specific antibody and neutralizing activity during natural cytomegalovirus infection publication-title: Journal of Medical Virology – volume: 21 start-page: 517 year: 1985 end-page: 521 article-title: Antibody response to cytomegalovirus polypeptides captured by monoclonal antibodies on the solid phase in enzyme immunoassays publication-title: Journal of Clinical Microbiology – volume: 73 start-page: 2375 year: 1992 end-page: 2383 article-title: Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain‐common and strain‐specific antibodies publication-title: Journal of General Virology – volume: 158 start-page: 449 year: 1988 end-page: 456 article-title: Cytomegalovirus infection in patients with AIDS publication-title: Journal of Infectious Diseases – volume: 62 start-page: 1066 year: 1988 end-page: 1070 article-title: Human immune responses to major human cytomegalovirus glycoprotein publication-title: Journal of Virology – volume: 65 start-page: 138 year: 1991 end-page: 146 article-title: Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus publication-title: Journal of Virology – volume: 73 start-page: 983 year: 1992 end-page: 988 article-title: The amino terminus of human cytomegalovirus glycoprotein B contains epitopes that vary among strains publication-title: Journal of General Virology – volume: 5 start-page: 29 year: 1996 end-page: 35 article-title: Current prospects for immunization against cytomegaloviral disease publication-title: Infectious Agents and Disease – volume: 201 start-page: 263 year: 1994 end-page: 276 article-title: Function of human cytomegalovirus glycoprotein B: Syncytium formation in cells constitutively expressing gB is blocked by virus‐neutralizing antibodies publication-title: Virology – volume: 23 start-page: 157 year: 1989 end-page: 168 article-title: A rapid micro‐neutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus publication-title: Journal of Virological Methods – volume: 12 start-page: 827 year: 1990 end-page: 838 article-title: Vaccines for the prevention of human cytomegalovirus infection publication-title: Review of Infectious Diseases – volume: 77 start-page: 61 year: 1996 end-page: 74 article-title: Role of apical and basolateral membranes in replication of human cytomegalovirus in polarized retinal pigment epithelial cells publication-title: Journal of General Virology – volume: 84 start-page: 769 year: 1996 end-page: 799 article-title: The human cytomegalovirus US 11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol publication-title: Cell – volume: 165 start-page: 381 year: 1992 end-page: 384 article-title: Antibodies to recombinant‐derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity publication-title: Journal of Infectious Diseases – volume: 216 start-page: 133 year: 1996 end-page: 145 article-title: Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures publication-title: Virology – volume: 171 start-page: 1599 year: 1995 end-page: 1603 article-title: Dramatic interstrain differences in the replication of human cytomegalovirus in SCID‐hu mice publication-title: Journal of Infectious Diseases – volume: 36 start-page: 933 year: 1982 end-page: 942 article-title: Electrophoretic analysis of polypeptides immune precipitated from extracts of cytomegalovirus infected cells by human sera publication-title: Infection and Immunity – volume: 73 start-page: 2913 year: 1992 end-page: 2921 article-title: Assembly of conformation‐dependent neutralizing domains on human cytomegalovirus glycoprotein B publication-title: Journal of General Virology – volume: 209 start-page: 580 year: 1995 end-page: 591 article-title: Mutated forms of human cytomegalovirus glycoprotein B are impaired in inducing syncytium formation publication-title: Virology – volume: 64 start-page: 1079 year: 1990 end-page: 1085 article-title: Cell surface expression of human cytomegalovirus (HCMV) gp55‐116 (gB): Use of HCMV‐recombinant vaccinia virus‐infected cells in analysis of the human neutralizing antibody response publication-title: Journal of Virology – volume: 58 start-page: 661 year: 1986 end-page: 664 article-title: Immune responses to isolated human cytomegalovirus envelope proteins publication-title: Journal of Virology – volume: 90 start-page: 104 year: 1993 end-page: 108 article-title: Human cytomegalovirus in a SCID‐hu mouse: Thymic epithelial cells are prominent targets of viral replications publication-title: Proceedings of the National Academy of Sciences of the United States of America – volume: 307 start-page: 477 year: 1982 end-page: 479 article-title: Cytomegalovirus infection in a day‐care center publication-title: New England Journal of Medicine – volume: 49 start-page: 124 year: 1996 end-page: 131 article-title: Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B publication-title: Journal of Medical Virology – volume: 174 start-page: 606 year: 1996 end-page: 609 article-title: Interstrain variations in the cytomegalovirus (CMV) glycoprotein B gene sequence among CMV‐infected children attending six day care centers publication-title: Journal of Infectious Diseases – start-page: 227 year: 1993 end-page: 255 – volume: 174 start-page: 387 year: 1996 end-page: 392 article-title: Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines publication-title: Journal of Infectious Diseases – volume: 70 start-page: 979 year: 1989 end-page: 985 article-title: A major neutralizing domain maps within the carboxyl‐terminal half of the cleaved cytomegalovirus B glycoprotein publication-title: Journal of General Virology – volume: 8 start-page: 130 year: 1990 end-page: 136 article-title: Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune‐responses in human volunteers publication-title: Vaccine – volume: 71 start-page: 2443 year: 1990 end-page: 2450 article-title: The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino‐terminal part of the precursor molecule and contains a neutralizing epitope publication-title: Journal of General Virology – volume: 3 start-page: 9 year: 1994 end-page: 28 article-title: Function of glycoprotein B homologues of the family herpesviridae publication-title: Infectious Agents and Disease – volume: 161 start-page: 214 year: 1990 end-page: 219 article-title: Antiviral antibody responses in mothers and their newborn infants with clinical and subclinical congenital cytomegalovirus infections publication-title: Journal of Infectious Diseases – volume: 68 start-page: 1457 year: 1987 end-page: 1461 article-title: Human monoclonal antibodies neutralizing human cytomegalovirus publication-title: Journal of General Virology – volume: 39 start-page: 100 year: 1983 end-page: 108 article-title: Cytomegalovirus infected cell polypeptides immune precipitated by children with congenital and perinatal cytomegalovirus infections publication-title: Infection and Immunity – volume: 164 start-page: 362 year: 1988 end-page: 372 article-title: Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies publication-title: Virology – volume: 5 start-page: 1995 year: 1989 end-page: 2001 article-title: Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus publication-title: Journal of Virology – volume: 65 start-page: 1644 year: 1991 end-page: 48 article-title: The N‐terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B‐ and T‐cell immune responses in ns publication-title: Journal of Virology – volume: 70 start-page: 78 year: 1996 end-page: 83 article-title: Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains publication-title: Journal of Virology – start-page: 803 year: 1994 end-page: 807 – volume: 72 start-page: 3017 year: 1991 end-page: 3023 article-title: Characterization of a major antigenic region on gp55 of human cytomegalovirus publication-title: Journal of General Virology – start-page: 145 year: 1993 end-page: 148 – volume: 67 start-page: 703 year: 1993 end-page: 710 article-title: Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies publication-title: Journal of Virology – year: 1991 – volume: 66 start-page: 5290 year: 1992 end-page: 5297 article-title: A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus publication-title: Journal of Virology – volume: 139 start-page: 73 year: 1984 end-page: 86 article-title: Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies publication-title: Virology – volume: 70 start-page: 979 year: 1989 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB5 publication-title: Journal of General Virology doi: 10.1099/0022-1317-70-4-979 – volume: 43 start-page: 77 year: 1994 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB25 publication-title: Journal of Medical Virology doi: 10.1002/jmv.1890430115 – volume: 174 start-page: 387 year: 1996 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB50 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/174.2.387 – volume: 164 start-page: 835 year: 1991 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB42 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/164.5.835 – volume: 37 start-page: 814 year: 1996 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB13 publication-title: Investigative Ophthalmology and Visual Science – volume: 68 start-page: 1457 year: 1987 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB26 publication-title: Journal of General Virology doi: 10.1099/0022-1317-68-5-1457 – start-page: 195 volume-title: Progress in Cytomegalovirus Research: Proceedings of the Third International Cytomegalovirus Workshop year: 1991 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB37 – volume: 161 start-page: 214 year: 1990 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB7 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/161.2.214 – volume: 5 start-page: 29 year: 1996 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB1 publication-title: Infectious Agents and Disease – volume: 72 start-page: 3017 year: 1991 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB44 publication-title: Journal of General Virology doi: 10.1099/0022-1317-72-12-3017 – volume: 21 start-page: 517 year: 1985 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB12 publication-title: Journal of Clinical Microbiology doi: 10.1128/JCM.21.4.517-521.1985 – volume: 66 start-page: 5290 year: 1992 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB49 publication-title: Journal of Virology doi: 10.1128/JVI.66.9.5290-5297.1992 – volume: 84 start-page: 769 year: 1996 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB51 publication-title: Cell doi: 10.1016/S0092-8674(00)81054-5 – volume: 73 start-page: 2375 year: 1992 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB28 publication-title: Journal of General Virology doi: 10.1099/0022-1317-73-9-2375 – volume: 65 start-page: 1644 year: 1991 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB22 publication-title: Journal of Virology doi: 10.1128/JVI.65.3.1644-1648.1991 – volume: 39 start-page: 100 year: 1983 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB35 publication-title: Infection and Immunity doi: 10.1128/IAI.39.1.100-108.1983 – volume: 158 start-page: 449 year: 1988 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB14 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/158.2.449 – volume: 71 start-page: 2443 year: 1990 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB27 publication-title: Journal of General Virology doi: 10.1099/0022-1317-71-10-2443 – volume: 64 start-page: 1079 year: 1990 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB9 publication-title: Journal of Virology doi: 10.1128/JVI.64.3.1079-1085.1990 – volume: 3 start-page: 9 year: 1994 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB33 publication-title: Infectious Agents and Disease – volume: 164 start-page: 362 year: 1988 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB23 publication-title: Virology doi: 10.1016/0042-6822(88)90549-1 – volume: 307 start-page: 477 year: 1982 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB32 publication-title: New England Journal of Medicine doi: 10.1056/NEJM198208193070804 – volume: 77 start-page: 61 year: 1996 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB47 publication-title: Journal of General Virology doi: 10.1099/0022-1317-77-1-61 – volume: 90 start-page: 104 year: 1993 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB29 publication-title: Proceedings of the National Academy of Sciences of the United States of America doi: 10.1073/pnas.90.1.104 – volume: 36 start-page: 933 year: 1982 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB34 publication-title: Infection and Immunity doi: 10.1128/IAI.36.3.933-942.1982 – volume: 73 start-page: 983 year: 1992 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB6 publication-title: Journal of General Virology doi: 10.1099/0022-1317-73-4-983 – start-page: 227 volume-title: The Human Herpesviruses year: 1993 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB2 – volume: 73 start-page: 2913 year: 1992 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB41 publication-title: Journal of General Virology doi: 10.1099/0022-1317-73-11-2913 – volume: 70 start-page: 78 year: 1996 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB11 publication-title: Journal of Virology doi: 10.1128/JVI.70.1.78-83.1996 – volume: 65 start-page: 138 year: 1991 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB19 publication-title: Journal of Virology doi: 10.1128/JVI.65.1.138-146.1991 – volume: 43 start-page: 386 year: 1994 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB4 publication-title: Journal of Medical Virology doi: 10.1002/jmv.1890430412 – volume: 49 start-page: 124 year: 1996 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB18 publication-title: Journal of Medical Virology doi: 10.1002/(SICI)1096-9071(199606)49:2<124::AID-JMV9>3.0.CO;2-7 – volume: 12 start-page: 827 year: 1990 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB40 publication-title: Review of Infectious Diseases doi: 10.1093/clinids/12.Supplement_7.S827 – volume: 201 start-page: 263 year: 1994 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB45 publication-title: Virology doi: 10.1006/viro.1994.1291 – start-page: 145 volume-title: Progress in Cytomegalovirus Research: Proceedings of the Third International Cytomegalovirus Workshop year: 1993 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB38 – volume: 209 start-page: 580 year: 1995 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB46 publication-title: Virology doi: 10.1006/viro.1995.1290 – volume: 58 start-page: 661 year: 1986 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB15 publication-title: Journal of Virology doi: 10.1128/JVI.58.2.661-664.1986 – volume-title: Cytomegalovirus: Biology and Infection year: 1991 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB17 doi: 10.1007/978-1-4757-9942-2 – volume: 216 start-page: 133 year: 1996 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB43 publication-title: Virology doi: 10.1006/viro.1996.0040 – volume: 62 start-page: 3309 year: 1988 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB8 publication-title: Journal of Virology doi: 10.1128/JVI.62.9.3309-3318.1988 – volume: 174 start-page: 606 year: 1996 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB20 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/174.3.606 – volume: 8 start-page: 130 year: 1990 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB16 publication-title: Vaccine doi: 10.1016/0264-410X(90)90135-9 – volume: 197 start-page: 143 year: 1993 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB30 publication-title: Virology doi: 10.1006/viro.1993.1575 – volume: 67 start-page: 703 year: 1993 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB31 publication-title: Journal of Virology doi: 10.1128/JVI.67.2.703-710.1993 – volume: 171 start-page: 1599 year: 1995 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB10 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/171.6.1599 – volume: 165 start-page: 381 year: 1992 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB24 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/165.2.381 – volume: 139 start-page: 73 year: 1984 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB36 publication-title: Virology doi: 10.1016/0042-6822(84)90331-3 – start-page: 803 volume-title: Vaccines year: 1994 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB39 – volume: 62 start-page: 1066 year: 1988 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB21 publication-title: Journal of Virology doi: 10.1128/JVI.62.3.1066-1070.1988 – volume: 5 start-page: 1995 year: 1989 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB48 publication-title: Journal of Virology doi: 10.1128/JVI.63.5.1995-2001.1989 – volume: 23 start-page: 157 year: 1989 ident: 10.1002/(SICI)1096-9071(199708)52:4<451::AID-JMV18>3.0.CO;2-J-BIB3 publication-title: Journal of Virological Methods doi: 10.1016/0166-0934(89)90129-8 |
SSID | ssj0008922 |
Score | 1.7071246 |
Snippet | Sera from patients with primary human cytomegalovirus (HCMV) infections, both acute and convalescent phase, and from HCMV‐seropositive healthy subjects were... Sera from patients with primary human cytomegalovirus (HCMV) infections, both acute and convalescent phase, and from HCMV-seropositive healthy subjects were... |
SourceID | proquest pubmed pascalfrancis crossref wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 451 |
SubjectTerms | Acute Disease Animals Antibodies, Monoclonal - metabolism Antibodies, Viral - blood Antigens, Viral - genetics Binding, Competitive Biological and medical sciences Carrier State - immunology Case-Control Studies COS Cells Cytomegalovirus - genetics Cytomegalovirus - immunology Cytomegalovirus - pathogenicity Cytomegalovirus Infections - immunology Cytopathogenic Effect, Viral Epitope Mapping epitope specificity Epitopes - genetics Fundamental and applied biological sciences. Psychology Human viral diseases Humans In Vitro Techniques Infectious diseases Medical sciences Mice Microbiology Neutralization Tests neutralizing antibodies Peptide Fragments - genetics Peptide Fragments - immunology Replicative cycle, interference, host-virus relations, pathogenicity, miscellaneous strains Sequence Deletion subunit vaccine syncytium formation Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Envelope Proteins - genetics Viral Envelope Proteins - immunology Virology |
Title | Humoral immune response to functional regions of human cytomegalovirus glycoprotein B |
URI | https://api.istex.fr/ark:/67375/WNG-199GCC9H-4/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2F%28SICI%291096-9071%28199708%2952%3A4%3C451%3A%3AAID-JMV18%3E3.0.CO%3B2-J https://www.ncbi.nlm.nih.gov/pubmed/9260696 https://www.proquest.com/docview/16309205 https://www.proquest.com/docview/79218075 |
Volume | 52 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1bb9MwFLamIU28cJ8IMPADRdtDuiR2Li4XacsubaW2ElDYm5U4NqoGCeoFMfgr_FjOidtMhSFekJD6kFqNT318fM534pPPhDzluQIz0JmrGM9crvLMTcLIuAIgkkiUiFSOieJgGHXHvH8Wnm2Q76t3YSw_RPPADVdG7a9xgWf5bP-SNBQA2Jte2oOE2QcY7kKS5yO1kRAx1rWLMIAp5i2W8tCHK_gc9I7c_uCdn7TYMWt77XTUYoeB2wf_7bMIefePXl9STyXC7kCAJ3EhhoVb5OVS9v4uyt1rpO5amXth0OEvQFqn00h6ZeU8Bylrce8aTuFXrMPMZjAVxp6hcRXIXcfMddA7uUl-rNRla13O24t53lbffmGS_E_6vEVuLME0PbDWf5ts6PIO2RosywXukjEYKzIQ0Am-BaPp1BYEazqvKAZ0-xyU4uEU0EwrQ-sjC6m6mFefNMTO6stkupjRDx8vVFUzWkxKeniPjE-O36Zdd3mOhKt45IMjiPMkNkWeZyIxxit0gNTMIWRyCQfEkyv4DjHa5wjufBYrbhKwbVYUJvG10mybbJZVqe8TmmDxJaSImTE-NywUUQFGzbXICg8alUOGq1mWny1diLTE0IGUqF7c8Y8kKlda1cowkFyCUqUEhcpaoZJJT6YjGci-Q57VttL0lk3PsRYvDuX74Sn2cZqmoiu5Q3bWjKm5IYC_zDhzyJOVcUnwILgtlJW6WswkIHJPBF7451_EAoAgYEuHbFurbDoXoMRIRA4Z1ab125j_MuSrRmwbHvzzHh-S65Z6GIs3H5HN-XShdwBQzvPH9cr_CSKKVOw |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1bb9MwFLbGJg1euE8EGPMDRdtDuiR2Li4XacsubVlbCVbYm5U4DqoGCeoFMcRf4b9yTtxmKgzxgoTUh9Zqferj43O-Y598JuQpTxWYgU5sxXhic5UmduQHuS0AIolIiUClmCj2-kF7yLtn_tkK-b54FsbwQ9QbbrgyKn-NCxw3pHcvWUMBgb3txB3ImF3A4TZkeS5yGwkRYmG78D2YY95gMfddeAevvc6B3e29c6MGO2RNpxkPGmzfs7vXyBoHoIKp28GbS_KpSJgzCPAlNkQxf528nAvf3UbBO7XYbSN0x_da_AWIa7VqUa-MoOcgZinyreEkfsVKzGQCk5GbWzSugrnLqLkKe0e3yI-Fwky1y3lzNk2b6tsvXJL_S6O3yc05nqZ7ZgHcISu6uEvWe_OKgXtkCPaKJAR0hA_CaDo2NcGaTkuKMd1shVK8nwKaaZnT6tZCqi6m5ScN4bP8MhrPJvTDxwtVVqQWo4Lu3yfDo8PTuG3Pr5KwFQ9c8AVhGoV5lqaJiPLcybSH7Mw-JHMRB9CTKvgMYdrliO9cFiqeR2DeLMvyyNVKsw2yWpSFfkBohPWXkCUmee7ynPkiyMCuuRZJ5kCjskh_Mc3ys2EMkYYb2pMS1YuH_oFE5UqjWul7kktQqpSgUFkpVDLpyHggPdm1yLPKWOrekvE5luOFvnzfP8Y-juNYtCW3yOaSNdU_8OAvM84ssrWwLglOBE-GkkKXs4kEUO4Iz_H__I1QABYEeGmRDWOWdecClBiIwCKDyrZ-G_NfhnzViE3Dw3_e4xa53j7tnciTTv_1I3LDMBFjLedjsjodz_Qm4Mtp-qRyAz8BlcpZCw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1bb9MwFLbGJlW8cJ8IMOYHiraHdElsJ3G5SFu2ri20RYPC3qzEsVE1aKZeEIO_wo_lOG4zFYZ4QULqQ2u1PvXxF5_vxCefEXpCMwkwUKkrCU1dKrPUjVmoXQ4UiceShzIziWKvH7aHtHvKTtfQ9-WzMFYforrhZq6Mcr02F_h5rvcuRUOBgL3tJB1ImH2g4S4keb6RNuI8MnXtnAUwxbROEsp8eAev_c6h2-299-M6OSINr5EM6uQgcLvX0AYNgYkYRnVyqT0Vc7sFAUuJC0GM1dCLhfG9HWN4tzK7Y43usqBJn4O5ZrMy9dIaegZmVgLfhpnDr6YQM53CXGh7iMZVLHeVNJdRr3UT_Vj6yxa7nDXms6whv_0iJfmfHHoL3Viwabxv4X8branxHVTrLeoF7qIhoNVIEOCReQxG4YmtCFZ4VmAT0e2NUGxOp4BmXGhcnlmI5cWs-KwgeBZfRpP5FH_8dCGLUtJiNMYH99CwdfQuabuLgyRcSUMfVoIoiyOdZ1nKY629XAVGm5lBKhdToDyZhM8QpH1q2J1PIkl1DOAmea5jX0lFNtH6uBir-wjHpvoScsRUa59qwniYA6qp4mnuQaN0UH85y-Lc6oUIqwwdCGHca7b8Q2GcK6xrBQsEFeBUIcChonSoIMITyUAEouugpyVWqt7SyZkpxouY-NA_Nn0cJwlvC-qgrRUwVT8I4C8TShy0vQSXgCXE7AulY1XMpwIouccDj_35GxEHJgjk0kGbFpVV5xycGPLQQYMSWr-N-S9DvmrEtuHBP-9xG9XeHLbE607_1UN03coQm0LOR2h9NpmrLSCXs-xxuQj8BBEhV7o |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Humoral+immune+response+to+functional+regions+of+human+cytomegalovirus+glycoprotein+B&rft.jtitle=Journal+of+medical+virology&rft.au=Navarro%2C+D&rft.au=Lennette%2C+E&rft.au=Tugizov%2C+S&rft.au=Pereira%2C+L&rft.date=1997-08-01&rft.issn=0146-6615&rft.volume=52&rft.issue=4&rft.spage=451&rft_id=info:doi/10.1002%2F%28SICI%291096-9071%28199708%2952%3A4%3C451%3A%3AAID-JMV18%3E3.0.CO%3B2-J&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon |